Related Experiment Video
Updated: May 17, 2026

Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules
Published on: December 16, 2021
Patient-specific protein aggregates in myofibrillar myopathies: laser microdissection and differential proteomics for
Sarah Feldkirchner1, Joachim Schessl, Stefan Müller
1Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany.
Abstract:
Myofibrillar myopathies (MFMs) are histopathologically characterized by desmin-positive protein aggregates and myofibrillar degeneration. While about half of all MFM are caused by mutations in genes encoding sarcomeric and extra-sarcomeric proteins (desmin, filamin C, plectin, VCP, FHL1, ZASP, myotilin, αB-crystallin, and BAG3), the other half of these diseases is due to still unresolved gene defects. The present study aims at the proteomic characterization of pathological protein aggregates in skeletal muscle biopsies from patients with MFM-causing gene mutations. The technical strategy is based on the dissection of plaque versus plaque-free tissue areas from the same individual patient by laser dissection microscopy, filter-aided sample preparation, iTRAQ-labeling, and analysis on the peptide level using offline nano-LC and MALDI-TOF-TOF MS/MS for protein identification and quantification. The outlined workflow overcomes limitations of merely qualitative analyses, which cannot discriminate contaminating nonaggregated proteins. Dependent on the MFM causing mutation, different sets of proteins were revealed as genuine (accumulated) plaque components in independent technical replicates: (i) αB-crystallin, desmin, filamin A/C, myotilin, PRAF3, RTN2, SQSTM, XIRP1, and XIRP2 (patient with defined MFM mutation distinct from FHL1) or (ii) desmin, FHL1, filamin A/C, KBTBD10, NRAP, SQSTM, RL40, XIRP1, and XIRP2 (patient with FHL1 mutation). The results from differential proteomics indicate that plaques from different patients exhibit protein compositions with partial overlap, on the one hand, and mutation-dependent protein contents on the other. The FHL1 mutation-specific pattern was validated for four patients with respect to desmin, SQSTM, and FHL1 by immunohistochemistry.
Insights
Myofibrillar myopathies (MFMs) involve protein aggregates. This study used proteomics to identify specific protein compositions within these aggregates, revealing mutation-dependent differences in patients with MFMs.
Area of Science:
- Muscle Diseases
- Proteomics
- Molecular Biology
Background:
- Myofibrillar myopathies (MFMs) are characterized by protein aggregates and myofibrillar degeneration.
- While some MFMs have known genetic causes, many remain genetically unresolved.
- Understanding the protein composition of aggregates is key to diagnosing and treating MFMs.
Purpose of the Study:
- To proteomically characterize pathological protein aggregates in skeletal muscle biopsies from MFM patients.
- To differentiate between genuine aggregate components and contaminating proteins.
- To identify mutation-dependent protein compositions in MFM aggregates.
Main Methods:
- Laser dissection microscopy to isolate plaque and plaque-free tissue.
- Filter-aided sample preparation and iTRAQ-labeling for quantitative proteomics.
- Offline nano-LC and MALDI-TOF-TOF MS/MS for peptide analysis and protein identification.
Main Results:
- Differential proteomics identified distinct sets of proteins in aggregates based on MFM-causing mutations.
- Proteins identified included αB-crystallin, desmin, filamin A/C, myotilin, FHL1, and SQSTM, among others.
- Aggregate protein composition showed partial overlap but also significant mutation-specific differences, validated by immunohistochemistry for FHL1 mutations.
Conclusions:
- MFM protein aggregates have partially overlapping yet mutation-dependent compositions.
- Proteomic analysis provides a deeper understanding of MFM pathogenesis.
- This approach aids in distinguishing genuine aggregate components and can inform future diagnostic strategies.
More Related Videos
12:58Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
Published on: September 12, 2019
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015